|
|
-
MBC has established the Nucleic Acid Testing (NAT) technology platform since 2004. Facilitated by the in-house molecular diagnostic technologies, MBC launched its first benchmark HLA kits (Morgan™ HLA SSP Typing Kits) to the global market in 2007 through an efficient vertical integration of products design, development, manufacturing, clinical studies, certification and marketing. This technology platform serves as the core for future expansion of products in the field of NAT pathogen detection kits, and for a further integration of fully automated workstation machinery with MBC's NAT kits.
MBC's NAT business strategy is to establish partnerships through M&A to leverage upstream novel NAT technologies to downstream manufacturing and marketing of state-of-the-art molecular diagnostic products. To achieve this, MBC's merged a North America biotech company in 2004, and acquired an SFDA certified GMP manufacturing facilities through its subsidiary, Texas BioGene (TBG) in 2007. The action enabled MBC to launch a range of niche products to the market, particularly in the Great China area. Currently, China operation is located in Shanghai (China), with a working force of more than 50. In addition to the HLA kits (Morgan™ HLA SSP Typing Kits), which is sold in USA, Germany, Ireland, Turkey, Bulgaria, India, Vietnam, Malaysia, Taiwan and China, MBC's operation in China has completed a 100,000 clinical tests panel, and has submitted this one-step NAT product (HIV/HBV/HCV diagnostics) to China's SFDA for marketing approval in March 2008. With an anticipated approval of this product in the first half of 2009, MBC is aiming at a market penetration of up to 25% of blood banks and blood products manufacturers in China in 3-year. This business in China serves as a significant revenue source for MBC, not only for the short term, but also for mid and long terms with enormous growth potential. A similar business model can be duplicated in a number of South-east Asia emerging countries following SFDA's approval of these NAT products. In parallel with the developing/marketing force built in MBC and its subsidiaries, the corporate has just received its final inspection by reviewers of ASHI (American Society for Histocompatibility and Immunogenetics), and is expected to be certified in due course. This lab will provide quality NAT analysis services in a cost-effective manner for clinical applications.
-
The products portfolio from this NAT platform is expected to expand to cover a whole range of pathogen detection, hereditary diseases detection and other clinical uses. With the current cGMP facilities and business operation in China, MBC is aiming at becoming a major player for NAT diagnostic, not only in China market, but also in other Asian-pacific countries in the near future.
|
